Roche now depends on Xofluza to regain its dominance in the influenza market, however, resistance and mutation strains identified in Japan could make this an uphill battle for the pharma giant.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more